Abstract. Hypoxia plays a key role in tumour initiation and metastasis; one of the mechanisms is to induce epithelialmesenchymal transition (EMT). Signal transducer and activator of transcription 3 (STAT3) is involved in EMT by regulating the transcriptional regulators of E-cadherin, the biomarker of EMT. Until now, however, few studies have focused on the effects of STAT3 in hypoxia-induced EMT in tumour cells. The goal of this study was to investigate the roles of STAT3 in hypoxia-induced EMT in oesophageal squamous cell carcinoma (ESCC). The ESCC cells, TE-1 and EC-1, were incubated in normoxia, or in CoCl 2 , which was used to mimic hypoxia. With CoCl 2 , the ESCC cells showed increased migration and invasion abilities, accompanied with upregulation of HIF-1α, STAT3, and vimentin, and downregulation of E-cadherin. Knockdown of STAT3 inhibited EMT of ESCC cells and downregulated HIF-1α in vitro and in vivo. In ChIP assays, STAT3 bound to the promoter of HIF-1α, suggesting that STAT3 regulates transcription of HIF-1α. In conclusion, hypoxia induces EMT of ESCC, and STAT3 regulates this process by promoting HIF-1α expression.
Introduction
Hypoxic microenvironments exist in various malignant carcinomas, leading to angiogenesis, tumourigenesis, and metastasis of neoplasms. One of the mechanisms is that hypoxia can induce epithelial-mesenchymal transition (EMT), a crucial step in embryological development and cancer progression.
In EMT, the epithelial cells lose cell-to-cell tight junctions and baso-apical polarity, adopt mesenchymal cell phenotypes and plasticity, and become mobile (1, 2) . Loss of the epithelial markers, E-cadherin and β-catenin, and acquisition of the mesenchymal markers, vimentin, N-cadherin, and fibronectin, are the molecular hallmarks of EMT.
Hypoxia-induced EMT was found in a number of carcinomas, including colon, breast, pancreatic, and ovarian carcinomas, and hepatoblastoma (3) . Hypoxia inducible factors (HIFs) regulate hypoxic responses, including malignant biological behaviour in tumour cells. HIF-1 is the most important factor, and is composed of two subunits, HIF-1α and HIF-1β. The HIF-1α subunit is regulated by oxygen tension, whereas HIF-1β is constitutively expressed. HIF-1 targets the hypoxia-responsive genes (HRE), including the transcriptional regulators (Snail, Slug, Twist, ZEB) of E-cadherin (4) . It has been proposed that long-term hypoxia drives a perpetual EMT through upregulation of the zinc finger, E-box binding, homeobox protein, ZEB2, whereas short-term hypoxia induces a reversible EMT that requires Twist1 (5) . Hypoxia also is involved in EMT-triggering pathways of TGF-β, Notch, NFκB, Wnt, and PI3K (6) (7) (8) (9) (10) . However, the underlying mechanisms of how these multigene interactive cascades are triggered are still unknown.
Signal transducer and activator of transcription 3 (STAT3), a member of the STAT family of transcription factors that is activated through various mitogenic signalling pathways of cell growth, migration, and angiogenesis, is overexpressed and constitutively activated in a variety of human malignancies (11) . Studies have demonstrated that STAT3 is required for EMT. TGF-β induced EMT in pancreatic cancer requires STAT3 activity and Smad4-dependent signalling regulates this process (12) . Activation of EGFR or IL-6R results in high levels of STAT3 and activation of the downstream JAK2/STAT3 pathway, inducing a fibroblast-like morphology and migratory phenotype, consistent with the upregulation of mesenchyme-associated N-cadherin and vimentin, and the nuclear translocation of β-catenin (13) . EGF promotes EMT of cancer cells through a ROS/STAT3/HIF-1α/TWIST1/ N-cadherin signalling cascade (14) . STAT3 directly regulates the expression of genes encoding the transcription factors TWIST, ZEB1, and Snail (15) (16) (17) . STAT3 and associated EMT may contribute to chemoresistance, by involving EGFR signalling (18, 19) .
Overexpression of HIF-1α and STAT3 has been detected in numerous cancers, and these proteins play important roles in cancer progression and migration. Activated STAT3 increases HIF-1α protein levels by enhancing HIF-1α stability and accelerating its de novo synthesis (20) . STAT3 activates HIF1 target genes by binding to their promoters, interacting with HIF1α, and recruiting the coactivators, CREB binding protein (CBP) and p300, and RNA polymerase II (Pol II) to form enhanceosome complexes (21) . Stat3 regulates expression of Akt, which is required for growth signal-induced HIF-1 upregulation (22) . However, the role of STAT3 in hypoxia-induced EMT has not been reported.
Oesophageal carcinoma is the fourth most prevalent malignancy in China and the sixth cause of cancer-related death in the world. Oesophageal squamous cell carcinoma (ESCC) is one of the major histopathological subtypes of oesophageal cancer. Metastasis and chemo/radio resistance of ESCC are closely related to hypoxic conditions and EMT. This study investigated the mechanisms of hypoxia-induced EMT in ESCC and the roles of STAT3 in this process.
Materials and methods
Cell culture. Human ESCC cell lines TE-1 and EC-1 were purchased from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). The cells were grown in RPMI-1640 supplemented with 10% foetal bovine serum (FBS) and 1% penicillin/streptomycin. The cells were incubated under the normoxic condition of 20% O 2 , or in the presence of cobalt chloride (CoCl 2 ; Sigma, St. Louis, USA), a known hypoxia-inducing agent (23) .
Reverse transcription-PCR (RT-PCR) and real-time PCR (qPCR).
Total RNA Extraction, RT-PCR, and qPCR were performed as previously described (3). Total cellular RNA was extracted with the Ultrapure RNA kit (CW Biotech Co., Beijing, China). First-strand cDNA was synthesized with oligo (dT) primers (Sangon Biotech. Shanghai, China) and the Super RT cDNA kit (CW Biotech Co.). The primer sequences were as follows: E-cadherin forward: 5'-GAGAACGCATTGCC ACATACAC-3', reverse: 5'-GAGCACCTTCCATGACAGA CCC-3'; vimentin forward: 5'-ATGTGGATGTTTCCAAG CCTGAC-3', reverse: 5'-GAGTGGGTATCAACCAGAGG GAGT-3'; HIF-1α forward: 5'-CACTGCACAGGCCACA TTCACGT-3', reverse: 5'-GAGCACCTTCCATGACAGA CCC-3'; STAT3 forward: 5'-GAGAACGCATTGCCACAT ACAC-3', reverse: 5'-TCTGGCCGACAATACTTTCC-3'; and β-actin forward: 5'-GTCCACCGCAAATGCTTCTA-3', reverse: 5'-TGCTGTCACCTTCACCGTTC-3'. Products from RT-PCR were monitored by polyacrylamide gel electrophoresis (PAGE). qPCR was performed using the UltraSYBR Mixture (CW Biotech Co.) and ABI 7300 Real-time PCR system. To normalize the amount of input RNA, PCR was performed with probe and primers for β-actin.
Immunoblotting. Cells were harvested and incubated with RIPA buffer for 10 min to collect the cell lysates. The total cellular protein was separated using 10% SDS-PAGE and transferred to PVDF membranes (Millipore Corp., Bedford, MA, USA). PVDF membranes were blocked with TRIS buffered saline (TBS) containing 5% non-fat milk, and then incubated with the primary antibody at 4˚C overnight, followed by incubation with goat anti-rabbit/mouse secondary antibodies (1:10000, Odessey, China). The primary antibodies included anti-HIF-1α (1:1000, Abcam), anti-E-cadherin (1:2000, Abcam), anti-β-actin (1:10000, Sigma), anti-STAT3 (1:2000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-p-STAT3 (Tyr705) (1:2000, Santa Cruz Biotechnology), and anti-vimentin (1:2000, Abcam), anti-GAPDH (1:1000, Santa Cruz Biotechnology). Protein-antibody complexes were visualised using the ECL detection system (Mbchem, Shanghai, China) following the manufacturer's protocol. β-actin or GAPDH was used as an internal control.
Immunofluorescence. The cells were grown on coverslips in 24-well plates. Before staining, the cells were fixed with 4% formaldehyde for 10 min, followed by 0.2-0.3% Triton X-100 for 10 min and then were blocked in 1% BSA for 1 h. For staining, the cells were incubated with the primary antibodies monoclonal anti-E-cadherin ( Immunohistochemistry. E-cadherin, vimentin, HIF-1α, or pSTAT3 protein expression in tissue was detected by immunohisto chemistry. Sections (4 µm) were 10% formalinfixed, paraffin-embedded, deparaffinized in xylene, and then rehydrated through graded ethanol solutions. The slides were incubated in 10 mM citrate buffer (pH 6.0) at 95˚C for 20 min, followed by 3% hydrogen peroxide in methanol for 10 min, and then were blocked with 10% bull serum albumin for 10 min in room temperature. The tissue slides were incubated with anti-E-cadherin (1:100, Santa Cruz Biotechnology), anti-vimentin (1:100, Santa Cruz Biotechnology), anti-HIF-1α (1:100, Santa Cruz Biotechnology), or anti-pSTAT3 antibody (1:100, Santa Cruz Biotechnology) at 4˚C overnight, and with goat anti-rabbit/mouse secondary antibody (1:200, Santa Cruz Biotechnology) for 30 min at room temperature. The sites of antibody binding were visualized by 0.05% diaminobenzidine (DAB) and stained with Mayer's hematoxylin. The slides were scored in a blinded manner by two independent pathologists. The intensity of protein expression was calculated by summing the percentage of positively stained cells and the staining intensity.
Small interfering RNA (siRNA) and Small hairpin RNA (shRNA) transfection. Human HIF-1α siRNA (Santa Cruz Biotechnology) and STAT3 shRNA-expressing plasmid vector were used in the study. The oligonucleotide encoding an shRNA targeting 5'-TGTTCTCTATCAGCACAAT-3', starting at position 466 in the STAT3 sequence (GenBank Accession number: NM 39276) was cloned between the HpaI and XhoI restriction sites of the plasmid pGCL-GFP, which containing a CMV-driven GFP reporter (24) , to constructed a vector mediating RNAi (RNA interference) against STAT3 (pGCL-GFP-STAT3siRNA). HIF-1α siRNA, empty vector PGCL-GFP, or pGCL-GFP-STAT3siRNA was transfected into cells using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions.
Chromatin immunoprecipitation (ChIP)
. TE-1 and EC-1 cells were cultured in 100-mm dishes at a density of 1x10 6 /dish, serum-starved overnight, and then cross-linked with 1% formaldehyde. Chromatin preparation and immunoprecipitation were as previously described (15, 25) . Chromatin was fragmented by sonication and was incubated with anti-STAT3 (Santa Cruz Biotechnology) for the experiment, anti-RNA polymerase II (Pol II) (Santa Cruz Biotechnology) for the positive control, or rabbit polyclonal IgG (Santa Cruz Biotechnology) for the negative control for 3 h at 4˚C. Immunoprecipitation complex was collected by vortexing with protein A/G agarose and extensive washed, eluted, and purified. Then the DNA was used directly as template for PCR detection. The possible binding sites of HIF-1α were analysed using Primer Wound healing migration assay. TE-1 and EC-1 were seeded in 6-well plates, and wounds were made by scratching the plates with sterile 200 µl pipet tips, five scratches per well. Cells were allowed to continue growing in normoxia or with CoCl 2 (100 µmol/l) in 5% CO 2 at 37˚C. Images were taken at different times. The widths of the scratches were measured at five different regions and are presented as mean ± SD.
Invasion assay. Twenty-four-well invasion chambers (Corning Inc., Corning, NY, USA) coated with Matrigel (BD Biocoat) were used as described previously (25) . Starved cells (cultured in serum-free medium for 12 h before use) were added to the rehydrated inserts with serum-free RPMI-1640, and 10% FBS RPMI-1640 was added into the wells. One well of each plate was left as a blank. The chambers were incubated in normoxia or with CoCl 2 (100 µmol/l) for 12 h. The cells that passed through the filters to the lower surface of the insert chambers were stained with 0.1% crystal violet, and then counted.
Tumour xenografts. All animal work was done in accordance with a protocol approved by the Laboratory Animal Management Committee of Zhengzhou University. Six-week-old male, athymic, nude mice were used for the xenografting experiment. EC-1 (1x10 6 ) cells, mixed with an equal volume of Matrigel, were implanted subcutaneously into the dorsal regions of mice. Mice were treated with normal saline (as control), empty vector pGCL-GFP, or STAT3 siRNA by tail vein injection from day 7 after tumour implantation, twice a week. PGCL-GFP or STAT3 siRNA was mixed with lipofecter (Beyotime, Jiangsu, China) before injection (26, 27) . Four weeks after implantation, mice were euthanized and the tumour sizes were measured. Expression of pSTAT3, HIF-1α, E-cadherin, and vimentin in the xenografts tumour was detected by immunohistochemistry.
Statistical analyses. Statistical analyses were performed using IBM SPSS Statistics 21.0 (SPSS Inc. IBM, Armonk, NY, USA). Differences between two groups were assessed using the Student's t-test. Differences among three or more groups were evaluated using one-way ANOVAs. Data are shown as mean ± SD from three independent experiments. P-values <0.05 were considered statistically significant.
Results

Hypoxia induces EMT and activates STAT3 in ESCC cells.
Hypoxia induces several kinds of tumour cells to transform from epithelium to mesenchyme, both morphologically and biologically. The tumours include pancreatic, breast, ovarian, colon and hepatocellular cancers (28, 29) . However, there are few studies focusing on hypoxia-induced EMT in ESCC. To explore the effects of hypoxia on ESCC cells, we observed the morphological changes and the migration and invasion abilities of the ESCC cells, EC-1 and TE-1, in normoxia or hypoxia. The ESCC cells had the morphology of mesenchymal cells: spindle shaped with more pseudopodia in hypoxia or with CoCl 2 (Fig. 1A) . The migration and invasion rates of ESCC cells were significantly enhanced in the hypoxia mimic, CoCl 2 , than in normoxia (P<0.05; Fig. 1B and C). The EMT biomarkers, E-cadherin and vimentin, and the hypoxic-response marker, HIF-1α, were detected in ESCC cells in normoxia and hypoxia. When exposed to CoCl 2 , mRNA and protein expression of E-cadherin decreased and vimentin increased to levels higher than those in normoxia. HIF-1α protein, but not mRNA, increased more sharply with CoCl 2 than in normoxia. Phosphorylated STAT3, the active state of STAT3, increased in hypoxia ( Fig. 1D and E) , which was consistent with earlier studies (30, 31) . Changes in EMT protein and HIF-1α expression in CoCl 2 were confirmed by immunofluorescence assay (Fig. 1F) . Previous studies have shown that protein levels of HIF-1α and pSTAT3 increase with CoCl 2 as they do in 'real' hypoxia, and that tumour cells performed similar EMTs in the hypoxia mimic, CoCl 2 . Thus, the above molecular changes were not only due to CoCl 2 treatment, but also were reflective of changes in 'real' hypoxia.
STAT3 regulates HIF-1α and EMT in hypoxia.
STAT3 plays important roles in EMT induced by TGFβ, EGF, or IL-6 (32,33). To determine the effects of STAT3 on EMT induced by hypoxia, we used STAT3 siRNA to knockdown STAT3 in ESCC EC-1 cells. STAT3 mRNA and phosphorylated protein were effectively silenced by STAT3 siRNA, both in normoxia and in hypoxia. STAT3 siRNA downregulated HIF-1α mRNA and protein expression in normoxia and hypoxia. The EMT markers E-cadherin and vimentin were upregulated and downregulated (P<0.05), respectively, and the tendencies were more evident in hypoxia, when transfected with STAT3 siRNA ( Fig. 2A-C) . The invasion and migration rates of the cells declined when treated with STAT3 siRNA (P<0.05), and this effect was stronger in hypoxia ( Fig. 2D and E) . The above results indicated that STAT3 knockdown regulates HIF-1α and obliterates EMT induced by hypoxia. To observe the effect of HIF-1α in hypoxia-induced EMT, we used HIF-1α siRNA to block the expression of HIF-1α, and found that, in hypoxia, inhibiting the expression of HIF-1α increases E-cadherin expression and reduces vimentin expression. Based on the results of blocking HIF-1α, inhibition of STAT3 by STAT3 siRNA can further increase E-cadherin level and reduce vimentin expression (Fig. 2F and G) .
STAT3 binds the promoter of HIF-1α gene.
STAT3 is a transcription factor that regulates gene expression and exerts its physiologic functions by binding to DNA. Previous studies indicated that STAT3 increases HIF-1α protein stability and interacts with HIF-1α to bind to HIF1 target gene promoters. We noted that STAT3 affected mRNA expression of HIF-1α in ESCC cell lines in normoxia and hypoxia conditions ( Fig. 2A) . To determine the specific mechanisms of HIF-1α regulation by STAT3, we used in vivo chromatin immunoprecipitation (ChIP) assays to detect STAT3 binding to the HIF-1α promoter (Fig. 3) . The results in Fig. 3A indicated the efficiency of the immunoprecipitation, and that STAT3 did not bind non-specifically to DNA. Eight pairs of primers were designed, covering 3 kbp upstream of the HIF-1α open reading frame (Fig. 3B) . As shown in Fig. 3C primer pairs 3, 6 , 7, and 8 produced visible bands, suggesting that STAT3 binds to regions on the HIF-1α promoter. The result shows that nuclear STAT3 binds to the HIF-1α promoter of ESCC cells.
STAT3 siRNA inhibits EMT and tumour progression of ESCC in vivo.
STAT3 regulates HIF-1α expression and hypoxiainduced EMT in ESCC in vitro. For in vivo experiments, athymic nude mice were implanted with xenografted human ESCC tumours. Mice were treated with STAT3 siRNA, or with the controls, empty vector pGCL-GFP or saline. Tumour sizes were smaller in the STAT3 siRNA treated group than in control groups (P<0.05) (Fig. 4A) . Lower expression of p-STAT3, HIF-1α and vimentin, and higher expression of E-cadherin, were detected in the treatment group than in the control groups. The target proteins did not show differences in the two control groups (Fig. 4B) . Taken together, these results indicated that STAT3 influences ESCC tumour proliferation by regulating EMT via HIF-1α in ESCC in vivo.
Discussion
Hypoxia is one of the driving factors of EMT, and HIF-1α is the key factor of this process. Previous studies have demonstrated hypoxia-induced EMT in breast, pancreatic, prostate, and colon cancers. This study demonstrated hypoxia-induced EMT in ESCC for the first time, which occurs through the upregulation of HIF-1α. When HIF-1α expression is inhibited, hypoxia can no longer induce EMT. In our previous study, we found that STAT3 regulates EMT by targeting the transcription factors TWIST, SLUG, and SNAIL, which regulate E-cadherin expression. Does STAT3 play a role in hypoxiainduced EMT. In this study, we found that EMT in hypoxia is reduced when STAT3 expression is silenced, indicating that STAT3 is important in hypoxia-induced EMT. ESCCs undergo EMT in normoxic conditions, as well, although weaker than in hypoxic condition. The EMT in normoxic condition also was attenuated by inhibiting STAT3, whereas HIF-1α at a low level. This phenomenon indicated that STAT3 regulates EMT in normoxic and in hypoxic conditions through different pathways. The specific signalling networks involved in STAT3-regulated EMT need further investigation.
HIF-1α and Stat3 are overexpressed in diverse cancers and both play key roles in cancer progression. STAT3 affects HIF-1α expression and works with HIF-1α to adjust hypoxic reactions. It was found that Stat3 is required for both basal and growth signal-induced expression of HIF-1α. STAT3 binds to the promoters of HIF1 target genes, interacting with HIF-1α protein and recruiting a DNA binding complex to promote transcription. Our study revealed the potential binding of STAT3 to the HIF-1α promoter in ESCC cells, indicating that STAT3 transcriptionally regulates HIF-1α expression. This is consistent with the results of previous studies (34) . The difference is, our study found three potential binding sites in the HIF-1α promoter, in addition to the Stat3 binding site at position-373, which may play different roles in HIF-1α transcription. HIF-1α mRNA levels do not increase in hypoxia, but when STAT3 was silenced, HIF-1α mRNA declined significantly. Perhaps the role of STAT3 is to maintain normal levels of HIF-1α mRNA. Does STAT3 interact with HIF-1α in EMT? Our experiment showed that HIF-1α and EMT were downregulated by STAT3 siRNA. This suggests that STAT3 affects EMT induced by hypoxia by regulating HIF-1α, which was previously shown to regulate transcriptional regulators of E-cadherin. Taken together with prior studies, STAT3 might adjust EMT by targeting transcriptional regulators of E-cadherin, directly or indirectly.
In conclusion, our study demonstrated, for the first time, a key role of STAT3 in hypoxia-induced EMT in ESCC. Tumour cells acquire stem cell-like and chemoresistant phenotypes from EMT. Our findings may explain the radio/chemo resistance of ESCC and the values of therapy that targets STAT3. Not all tumour cells undergo EMT, and the process rarely occurs during the entire process of tumour progression. When EMT cells arrive at their destination, these mesenchymal cells may undergo the reverse process, mesenchymal-epithelial transition (MET), and then adhere to and proliferate in the new organs. The heterogeneity of malignant tumour cells with mixed epithelial and mesenchymal traits may enhance the ability of these cells to adapt changes in the microenvironments, and to survive and evolve quickly. EMT is not the complete story of tumour progression. Further studies are required to clarify the precise mechanisms and signals that regulate the transition between epithelial and mesenchymal phenotypes, and the involvement of STAT3 and hypoxia in these processes.
